Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01060748Phase 2Completed

Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea

Role: lead

NCT00901654Phase 1Completed

ACE527 Safety and Immunogenicity Study

Role: lead

NCT00859716Phase 2Unknown

ACE393-103 Vaccination Challenge Study

Role: lead

NCT00434798Phase 1Unknown

Campylobacter Jejuni Challenge Model Development: Dose Ranging Study

Role: collaborator

All 4 trials loaded